The BIOEquality Agenda is a national effort in collaboration with our partners and member organizations in the biotechnology sector that aims to counteract the systemic inequality, injustice, and unfair treatment of underserved communities.
Biotechnology can be a positive force for change in these communities. BIO intends to leverage the existing efforts of BIO member companies to focus on 3 pillars of change.
Promote Health Equity
- Enhance clinical trial diversity by partnering with Contract Research Organizations and Minority Serving Institutions
- Foster enhanced nutritional, environmental, and mental wellness opportunities in economically disadvantaged communities
Invest in the Current and Next Generation of Scientists
- Inventory and promote visibility of industry-sponsored minority training programs
- Establish STEM training best practices for underrepresented populations
- Create a network of minority scientists and engineers
- Facilitate a partnering network, including hiring of industry-trained minority scientists and engineers
Expand Opportunity for Women and Other Underrepresented Populations
- Enhance use of minority- and women-owned small businesses in biotech supply chains, to promote economic development of marginalized communities and especially those, hard hit by COVID-19
- Promote diversity of the NIH SBIR Grants
The I AM BIO podcast spotlights diversity in clinical trials, vaccine education and overcoming the legacy of Tuskegee. Dr. Michelle interviews Tal Zaks, Chief Medical Officer of Boston biotech Moderna, about the company’s commitment to enroll people of color and vulnerable populations in its historic Phase 3 covid vaccine trial.